Interim results from the phase II COCOON trial showed a reduction in dermatologic adverse events for patients with EGFR-mutant non-small cell lung cancer (NSCLC) when proactive skincare is added to frontline treatment. The trial, led by Bishal Tiwari at Nassau University Medical Center, reported a 50% reduction in treatment-related skin toxicity. Because EGFR-targeted regimens frequently trigger rash and related skin events that can drive dose interruptions, COCOON’s interim readout targets a high-frequency tolerability bottleneck. The study is designed to evaluate whether early management strategies can preserve patients on therapy. For development teams, supportive-care evidence like this can affect how protocols are built around targeted oncology regimens—potentially improving real-world adherence even when the underlying anticancer agent remains unchanged.